Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Hofseth Biocare ASA ( (HOFBF) ) has issued an announcement.
HBC reported a 35% increase in full-year sales revenue to NOK 256.8 million, driven by premium products such as CalGo® and OmeGo® and strong performance in higher-margin B2B human nutrition segments. The company’s restructuring efforts improved scalability and margins, with significant growth in pet and feed segments and renewed consumer health division growth. Strategic advancements in the U.S. market, record-high long-term contracts, and ongoing R&D successes in health benefits and oncology research position HBC for continued growth and innovation in 2025.
More about Hofseth Biocare ASA
Hofseth BioCare ASA (HBC) is a Norwegian company focused on consumer and pet health, emphasizing sustainability and full traceability. The company repurposes salmon industry by-products into health-enhancing ingredients like ProGo®, OmeGo®, and CalGo®, which are targeted at improving human and pet health. HBC is committed to scientific research, leading to innovative health benefits and patented discoveries. The company operates globally, with headquarters in Ålesund, Norway, and is listed on the Oslo Stock Exchange.
Average Trading Volume: 16,725
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $112.4M
Learn more about HOFBF stock on TipRanks’ Stock Analysis page.
